Laurion Capital Management LP Cuts Stock Position in Bausch Health Companies Inc. (NYSE:BHC)

Laurion Capital Management LP lessened its holdings in Bausch Health Companies Inc. (NYSE:BHC - Free Report) by 11.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 2,743,465 shares of the company's stock after selling 340,591 shares during the quarter. Bausch Health Companies accounts for approximately 0.4% of Laurion Capital Management LP's holdings, making the stock its 18th largest holding. Laurion Capital Management LP owned 0.76% of Bausch Health Companies worth $22,112,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in BHC. Sanders Morris Harris LLC boosted its holdings in Bausch Health Companies by 16.0% in the fourth quarter. Sanders Morris Harris LLC now owns 28,975 shares of the company's stock worth $234,000 after acquiring an additional 4,000 shares in the last quarter. Merit Financial Group LLC purchased a new position in shares of Bausch Health Companies in the fourth quarter worth about $228,000. SG Americas Securities LLC raised its stake in shares of Bausch Health Companies by 62.0% in the fourth quarter. SG Americas Securities LLC now owns 3,301,981 shares of the company's stock worth $26,614,000 after purchasing an additional 1,263,706 shares during the last quarter. DGS Capital Management LLC purchased a new position in shares of Bausch Health Companies in the fourth quarter worth about $143,000. Finally, Tobam raised its stake in shares of Bausch Health Companies by 10.4% in the fourth quarter. Tobam now owns 15,034 shares of the company's stock worth $121,000 after purchasing an additional 1,422 shares during the last quarter. Institutional investors and hedge funds own 78.65% of the company's stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on BHC shares. Royal Bank of Canada raised their price objective on Bausch Health Companies from $8.50 to $10.00 and gave the stock a "sector perform" rating in a research note on Friday, May 2nd. StockNews.com cut Bausch Health Companies from a "buy" rating to a "hold" rating in a research note on Saturday, May 10th. Finally, Jefferies Financial Group restated a "hold" rating and issued a $8.00 price objective (down from $12.00) on shares of Bausch Health Companies in a research note on Thursday, February 6th. One analyst has rated the stock with a sell rating and seven have assigned a hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $7.42.

Bausch Health Companies Stock Performance

Shares of NYSE:BHC traded up $0.08 during trading on Friday, reaching $4.68. The stock had a trading volume of 1,151,316 shares, compared to its average volume of 2,610,353. The business has a fifty day moving average price of $5.55 and a 200-day moving average price of $6.97. The stock has a market cap of $1.69 billion, a PE ratio of -38.96, a PEG ratio of 0.37 and a beta of 0.34. Bausch Health Companies Inc. has a 1-year low of $3.96 and a 1-year high of $9.85.

Bausch Health Companies (NYSE:BHC - Get Free Report) last issued its quarterly earnings results on Wednesday, February 19th. The company reported $1.21 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.65 by ($0.44). The firm had revenue of $2.56 billion during the quarter, compared to analyst estimates of $2.51 billion. Bausch Health Companies had a negative return on equity of 577.82% and a negative net margin of 0.48%. Sell-side analysts expect that Bausch Health Companies Inc. will post 4.41 earnings per share for the current year.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.